Tabula Rasa HealthCare Announces Clinical Advisory Board for its Hospital Division
In this article:
Tom Lodise, PharmD, PhD Named Chairman
Moorestown, NJ, February 16, 2021 – Tabula Rasa HealthCare, Inc (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing safe use of medications, today announced the formation of its Hospital Division Clinical Advisory Board (CAB). This group of clinical leaders brings expertise from across the health system and infusion provider markets, and will provide guidance to help shape continuing innovation at TRHC, particularly through TRHC’s Bayesian dosing solution, DoseMeRx.
TRHC Chief Scientific Officer and CEO of TRHC’s Scientific Precision Pharmacotherapy Research & Development Institute Dr. Jacques Turgeon stated, “The addition of the Hospital Division’s Clinical Advisory Board will allow us to advance our research and experience in pharmacokinetics and pharmacodynamics and continue to enhance our pharmacy-focused clinical decision support software platforms”.
Thomas Lodise, PharmD, PhD, professor, Albany Pharmacy College of Health Sciences and clinical pharmacy specialist at the Stratton VA Medical Center, has been named chairman of the advisory board.
Dr. Lodise, an internationally known expert in antimicrobial pharmacokinetics and pharmacodynamics is co-author of the 2020 published revised consensus guideline and review for monitoring vancomycin in the treatment of serious methicillin-resistant Staphylococcus aureus infections.
“As a practicing clinician, I recognize research cannot improve patient care unless the knowledge is transferable. In the era of personalized medicine, we cannot apply a ‘one size fits all’ approach to dosing,” said Dr Lodise. “I’m excited in this modern era that Bayesian dosing software like DoseMeRx makes it possible to apply best clinical practices at the beside. There’s no better way to merge my research focus and clinical knowledge than to lead this CAB.”
Members of the TRHC Hospital Clinical Advisory Board include:
- Tom Lodise, PharmD, PhD (Chair); Albany College of Pharmacy and Health Sciences, Albany, NY
- Luigi Brunetti, PharmD, MPH, PhD, BCPS, BCGP; Robert Wood Johnson University Hospital, Somerset, NJ
- Jeff Cies, PharmD, MPH, BCPS-AQ ID, BCPPS; St. Christopher’s Hospital for Children, Philadelphia, PA
- Ethan Smith, PharmD, BCIDP; Cedars-Sinai, Los Angeles, CA
- William Musick, PharmD, BCIDP; Houston Methodist Hospital, Houston, TX
- Shivani Patel PharmD, BCPS; Memorial Hermann Southwest, Houston, TX
- Lucinda Van Anglen, PharmD; Healix Infusion Therapy, LLC, Houston, TX
“We are pleased to attract such a knowledgeable group of infectious disease and clinical pharmacy practitioners from leading health systems and infusion providers,” said Dr. Kristi Kuper, Director of Clinical Pharmacy, Hospital Division, TRHC. “Their knowledge, expertise, and best practices are invaluable in helping us continually improve and shape how precision medication dosing is applied at the patient’s bedside”.
For more information about the TRHC Hospital CAB please visit https://doseme-rx.com/clinical-advisory-board.
About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.
DoseMeRx® is a Tabula Rasa HealthCare solution and the first precision dosing software developed specifically for clinical practice. DoseMeRx’s clinical decision support solutions empower healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information, visit doseme-rx.com
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 2, 2020, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.
TRHC Media Contact
T: (215) 870-0829
TRHC Investor Contact
T: (866) 648-2767